(Q39339808)

11 September 2017

title

More multiarm randomised trials of superiority are needed (English)

1 reference

11 September 2017

James Carpenter

2

0 references

Matthew R Sydes

object named as

Matthew R Sydes

series ordinal

3

0 references

author name string

Mahesh K B Parmar

series ordinal

1

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

11 September 2017

1 reference

11 September 2017

volume

384

1 reference

11 September 2017

issue

9940

1 reference

11 September 2017

page(s)

283-284

1 reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

On the choice of doses for phase III clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

How Cancer Research UK is adapting to adaptive designs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Practical guidelines for multiplicity adjustment in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Multi-arm clinical trials of new agents: some design considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961122-3

7 January 2021

10.1016/S0140-6736(14)61122-3

Identifiers

DOI

1 reference

11 September 2017

1 reference